ClinicalTrials.gg

TargetBeta

TSLP

thymic stromal lymphopoietin

10 programs in company-led studies act on TSLP, from 10 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (5 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
tezepelumabruleAstraZenecaphase 4349 running–ChEMBL
tilrekimigPfizerphase 3119 runningIL13, IL4the company's pipeline
felcorekibartGlaxoSmithKlinephase 399 running–the company's pipeline
lunsekimigSanofiphase 3106 runningIL13the company's pipeline
SHR-1905Jiangsu HengRui Medicinephase 373 running–the company's pipeline
TQC2731Sino Biopharmaceuticalphase 373 running–the company's pipeline
WIN378ruleWindward Biophase 222 running–the studies' text
CDX-622ruleCelldex Therapeuticsphase 121 runningKITLGthe studies' text
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 111 runningIL33the studies' text
HY6725ruleNewsoara Biopharmaphase 111 runningIL33the studies' text

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.